December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

628.89 +5.47 (+0.88%)
Streaming Delayed Price Updated: 10:43 AM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
63 64 Next >
News headline image
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
News headline image
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga
News headline image
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling ↗
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year. 
Via Investor's Business Daily
Topics Stocks
News headline image
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
Via Investor's Business Daily
News headline image
Smart Money Is Betting Big In REGN Options ↗
 
Via Benzinga
News headline image
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
News headline image
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease ↗
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
News headline image
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Companies Will Split Their Stocks by 2027 ↗
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes. 
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030 ↗
These stocks have generally delivered competitive returns. 
Via The Motley Fool
News headline image
Biotech And Life Science Sector Update Summer Of 2024 ↗
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
News headline image
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Bagger Stocks: Can You Find One? ↗
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors. 
Via Talk Markets
News headline image
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment ↗
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment. 
Via Benzinga
News headline image
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.